About 28 million Americans have alcohol use disorder and fewer than one in forty receives medication for it, a gap telehealth firms and hospitals are now trying to close.
Key Takeaways
- The gap is the story: Roughly 28 million Americans meet the criteria for alcohol use disorder, and fewer than one in ten receive any treatment in a year. About 2.4 percent of adults with the diagnosis receive one of the approved medications.
- Supply was never the constraint: Naltrexone, acamprosate, and disulfiram have been available for decades, and oral naltrexone is an inexpensive generic that any licensed prescriber can write without a federal waiver. The barrier is that almost nobody offers it.
- Emergency departments are the clearest opening: Alcohol-related emergency visits have climbed sharply and pilot programs show medication can be started at discharge with measurable effect. Most departments still discharge these patients with a phone number.
- Telehealth is assembling the channel: Virtual alcohol programs now hold payer contracts, sell to employers, and operate across state lines, often on a reduction rather than abstinence model. The open question is whether payers will fund a condition most patients never name to a clinician.
A patient comes into an emergency department in the middle of the afternoon with a scalp laceration and a blood alcohol concentration that would flatten most people. He gets sutures, fluids, a sandwich, and four hours on a gurney. Somewhere around the third hour a resident asks about his drinking, and he answers honestly, because people usually do. Then he is discharged with a printed list of treatment programs, the phone numbers on which will connect him, if he calls, to waiting lists. Nobody offers him a prescription. This happens several million times a year in the United States, and it is the clearest illustration available of how the country’s most common substance use disorder is actually managed, which is to say barely.
Alcohol use disorder occupies a strange position in behavioral health. It is the largest single condition in the field by prevalence, it kills more Americans annually than opioid overdoses, it has three approved medications that work about as well as the drugs prescribed routinely for other chronic conditions, and it is almost entirely unserved as a market. For an industry that has spent fifteen years building infrastructure around opioid use disorder, the arithmetic ought to be uncomfortable.
Alcohol Use Disorder Is the Most Common and Least Treated Addiction
Federal survey numbers are consistent and unflattering. Somewhere near 28 million Americans aged twelve and older meet the diagnostic criteria for alcohol use disorder. Roughly 2.1 million of them, about 7.6 percent, received any form of treatment in the past year. Among the 27.1 million adults carrying the diagnosis, about 665,000, or 2.4 percent, received medication for it. The contrast with opioids is the number worth staring at: in the same survey year, 17 percent of people with opioid use disorder received medication for it, a rate roughly seven times higher.
Mortality figures have been moving in the wrong direction. Federal data attributes roughly 178,000 deaths a year to excessive alcohol use, a toll that rose 29 percent from the 2016 to 2017 period through 2020 to 2021. The increase among women, at nearly 35 percent, outpaced the increase among men. The economic estimate most often cited puts the annual cost of alcohol misuse near 249 billion dollars, about three quarters of which is lost workplace productivity rather than medical spending, which is one reason self-insured employers have become an unexpectedly receptive audience for anyone selling a solution.
Comparison with opioid use disorder is instructive without being flattering to either condition. Opioids produced a federal emergency declaration, a dedicated grant architecture, prescriber waiver reform, and a national naloxone distribution effort. Alcohol produced dietary guidelines. The clinical tools for alcohol were already in the formulary.
Why Approved Alcohol Medications Go Unprescribed
Three drugs carry an approval for alcohol use disorder: naltrexone, which blunts the reward associated with drinking and is available orally or as a monthly injection; acamprosate, which acts on withdrawal-related symptoms and requires three doses a day; and disulfiram, the oldest of them, which makes drinking physically unpleasant. Their effect sizes are modest but real, and comparable to what is accepted without controversy in other areas of medicine. A 2023 meta-analysis in JAMA, pooling 118 trials and nearly 21,000 participants, put the number needed to treat with oral naltrexone at eleven to keep one person from returning to heavy drinking. That is a better figure than plenty of routinely prescribed medicine achieves.
None of the obstacles here are pharmacological. Oral naltrexone is a generic, it is not a controlled substance, it requires no special registration, and any physician, nurse practitioner, or physician assistant with prescribing authority can write it during a routine visit. What is missing is the habit. Primary care clinicians screen for drinking inconsistently and often lack a next step when a screen is positive. Addiction programs built around abstinence and group process have historically been ambivalent about medication. Patients, for their part, rarely present asking for treatment for drinking, because the cultural framing of alcohol problems remains moral rather than medical, and because the treatment they imagine is twenty-eight days away from their job rather than a pill and a follow-up call.
Emergency Departments as an Untapped Point of Initiation
If the goal is to reach people who are not asking, the emergency department is where they already are. Alcohol-related emergency visits have risen roughly 47 percent over the past decade, and one analysis found that people with alcohol use disorder accounted for close to 4 percent of all emergency visits over a four-year span. These patients are frequently high utilizers, cycling through the same departments repeatedly, and the encounter itself functions as their primary contact with the health care system.
Small studies have begun testing whether medication can be started there, borrowing the playbook that made emergency department buprenorphine initiation a standard of care for opioid use disorder. A pilot at Mount Sinai published in early 2025 offered patients with moderate to severe alcohol use disorder a single dose of oral naltrexone, a two-week starter pack, and a referral. Of the patients enrolled, 29 percent were engaged in formal addiction treatment at fourteen days and 33 percent at thirty, and self-reported consumption fell from about five drinks a day to just over two. The trial was tiny, single-site, and unblinded, and its own screening numbers tell the more revealing story: of 761 patients screened, 21 enrolled.
Research into why uptake stays low keeps producing the same answers. Clinicians report that they were never taught to prescribe for alcohol, that they are unsure who owns the follow-up, and that the workflow is not built. A survey of emergency staff at one large academic health system found the barriers were mostly educational and procedural rather than clinical. None of this is exotic. It is the same implementation problem that took buprenorphine a decade to solve, and it suggests the constraint is operational, which is another way of saying it is addressable by someone willing to build the process.
Telehealth Platforms Are Building the Alcohol Treatment Market
The companies that noticed this earliest were virtual. Ria Health has been treating alcohol use disorder by telehealth since 2016, combining prescribed medication with coaching and connected breathalyzers, and it now operates in all fifty states with contracts across a list of national and regional plans that includes Anthem, Optum, Highmark, and Magellan. Monument, founded in 2018, sells both directly to consumers and as an employer benefit. Both organize their programs around a premise that traditional treatment tends to resist, which is that a patient may want to drink less rather than not at all, and both report outcomes in terms of movement between World Health Organization drinking risk levels rather than days of abstinence.
That framing is a market decision as much as a clinical one. Abstinence-only positioning limits the addressable population to people prepared to identify as alcoholics, a small fraction of the 28 million. Reduction-oriented programs can credibly serve the much larger group who would like to drink half as much and have no intention of walking into a church basement. The clinical evidence supports treating that goal as legitimate, and payers have been slowly persuaded, though coverage remains inconsistent enough that self-pay is still a meaningful share of the business.
The interesting question for operators is not whether the demand exists. It is whether alcohol treatment can be delivered inside the payment structures the field already has, or whether it requires new ones, a version of the problem that keeps behavioral health innovation lagging its own evidence base. A fifteen-minute medication management visit plus a coaching call does not resemble the intensive outpatient program that most substance use benefits were designed around, and it does not fill residential beds. The recent attention to GLP-1 drugs has made alcohol pharmacotherapy briefly fashionable among people who had never considered it. The more sobering point is that the treatments already approved have been available the entire time, sitting on a shelf that almost nobody reaches for.
